88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026 MONTPELLIER, France , July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading ... 2026-07-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. Demonstrated a unified quality system, strict risk assessment protocols, and compliance ... 2026-07-08T Health Care/Hospital Medical/Pharmaceuticals
Seegene Launches Industry's First Global Million Clinical Study to Shape New Disease-Specific Testing Standards Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. The study is designed to evaluate the clinical utility of syndromic ... 2026-07-08T Health Care/Hospital Medical/Pharmaceuticals
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in ... 2026-07-08T Biotechnology Environmental Products & Services Health Care/Hospital Medical/Pharmaceuticals
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects ... 2026-07-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy Up ... 2026-07-08T Health Care/Hospital Medical/Pharmaceuticals
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive ... 2026-07-07T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones MUMBAI, India , July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report ... 2026-07-07T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HKSH's First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate Minimises Cardiopulmonary Concerns and Maintains Quality of Life ... 2026-07-07T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Healome Therapeutics Closes ￡2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases BIRMINGHAM, England , July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface ... 2026-07-07T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved